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factors were associated with better survival: NC at freezing
(5.5  107/kg) (HR  0.25, p  0.004) and FLU containing
preparative regimen (HR  0.16, p  0.018). In patients re-
ceiving a higher cell dose, 2-y survival was 55% versus 16% for
those receiving a lower dose (p  0.005); it was 67% for those
receiving a FLU containing regimen compared to 25% (p 
0.016) for those receiving other regimens. We conclude that
results of UCBT for FA patients are acceptable and can be
improved by better selection of the CB units and use of FLU in
the preparative regimen.
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THE ROLE OF CD4CD25 T REGULATORY (TREG) CELLS IN ALLOGE-
NEIC BONE MARROW TRANSPLANTATION
Blazar, B.R.1, Panoskaltsis-Mortari, A.1, Levine, B.L.2, June, C.H.2,
Lucas, P.J.3, Gress, R.3, Serody, J.S.4, Taylor, P.A.1, 1. Pediatrics,
Univ. Minn, Minneapolis, MN; 2. Cancer Center, Univ. Penn, Phila-
delphia, PA; 3. NCI, Bethesda, MD; 4. Medicine, Microbiology and
Immunology and the Lineberger Comprehensive Cancer Center, UNC-
Chapel Hill, Chapel Hill, NC.
A subpopulation of CD4 T cells that co-expresses CD25, the
IL-2 receptor alpha chain, without evidence of prior activation, has
been shown to be important in self-tolerance by suppressing au-
toimmune responses. These CD4CD25 Treg cells are present
in rodents at a frequency of 8-12% of CD4 T cells and in humans
at lower frequencies (1-4%). In vitro, Treg cells are potent inhib-
itors of alloresponses. Depletion of either host CD25 cells prior
to BMT or donor CD25 cells in the donor graft inoculum
present markedly accelerated graft-versus-host disease (GVHD)
lethality. Whereas supplementing the donor graft with fresh
CD4CD25 Treg cells delayed GVHD lethality, adding ex vivo
activated and expanded Treg cells virtually abolished GVHD le-
thality. These data are consistent with the fact that activated Treg
cells are more potent suppressors than non-activated cells. In
studies in which CD4 effector T cells could be tracked in the
whole animal, Treg cells were found to suppress effector T cell
expansion or homing to lymphoid organs and GVHD target tis-
sues. Tregs that co-expressed high levels of the lymph node hom-
ing receptor, L-selectin, were far more potent than L-selectin lo
cells suggesting that homing of Tregs to secondary lymphoid
organs is critical to preventing alloresponse initiation in vivo. In
other studies, alloengraftment was markedly increased by the in-
fusion of ex vivo activated and expanded donor Treg cells that
expressed high levels of L-selectin. Such engraftment facilitation
was not dependent upon the capacity of host T cells to receive
TGF
 signals. We conclude that the infusion of ex vivo activated
and expanded CD4CD25 is a highly potent means of inhibiting
GVHD and facilitating alloengraftment. Based upon the known
effects of Tregs on suppressing GVHD, augmenting alloengraft-
ment and immune recovery and preserving graft-versus-leukemia
effects, it is clear that a clinical trial of CD425 merits consid-
eration in the context of allogeneic BMT.
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IMMUNE RECONSTITUTION FOLLOWING CORD BLOOD CELL TRANS-
PLANTATION
Weinberg, K. Childrens Hospital, Los Angeles, CA.
Immune reconstitution after hematopoietic stem cell transplan-
tation (HSCT) is a fundamental problem that affects the clinical
outcome of transplantation, regardless of the stem cell source.
Delays or defects in immune reconstitution contribute to suscep-
tibility to infections with viruses, fungi, and encapsulated bacteria,
EBV-lymphoproliferative disease, and possibly to relapse. Ulti-
mately, immune reconstitution depends on generation of new T
lymphocytes in the thymus, a process that depends on interactions
of thymocytes with thymic epithelial cells (TEC). Critical for TEC
support of thymopoiesis are the cytokines IL-7 and kit ligand (KL).
Umbilical cord blood cell transplantation (UCBCT) is increasingly
employed because of theoretical and empiric advantages such as
ready availability and decreased risk of graft-versus-host disease
(GVHD). Some of the features of UCBC that make them attractive
as a source of HSC may also contribute to difﬁculties in immune
reconstitution. However, this is very difﬁcult to analyze critically in
clinical HSCT because of the large number of technical differences
in transplant regimens, alloreactivity, and poorly understood vari-
ables such as donor and host variation in lymphopoiesis. One
approach to understanding the outcome of UCBCT is based on
analyzing the differences between the cellular components of
UCBC vs other sources of stem cells. All stem cell sources contain
mixtures of HSC, committed myeloid and lymphoid progenitors,
and mature lymphocytes. Analyses of myeloid recovery have shown
that HSC dose can be limiting, hence recommendations for a
minimum number of phenotypic progenitor cells required for
marrow recovery. Murine data from our laboratory suggests that
thymic recovery may also be related to the dose of infused HSC or
lymphoid progenitors. Although the number of HSC in UCBC
sources may be limiting, the increased proliferative potential of
cord blood HSC could also be advantageous. Besides reduced
numbers of T lymphocytes in UCBC, a major difference between
UCBC and other HSC sources, e.g., adult marrow or PBSC, is the
nature of the mature T lymphocytes present in each product. The
T lymphocytes in UCBC are predominantly naïve T lymphocytes
while adults have mainly memory T lymphocytes. Naïve T lym-
phocytes require a greater amount of antigen to stimulate in vitro,
compared to memory T lymphocytes. The decreased ability to
stimulate naïve T cells may account for reduced alloreactivity in
UCBC, but may also lead to decreased sensitivity to nominal
antigens such as viruses. Thus, USCBC recipients may gain less
protection from the adoptive transfer of mature T lymphocytes
than BMT or PBSCT recipients. In addition, T lymphocytes from
UCBC may have altered immune responses mediated by the ex-
posure to immunomodulators in the placental microcirculation,
e.g., G-CSF. Over the last ﬁve years, various studies have shown
that the maintenance of mature T lymphocyte numbers in the
periphery is mediated by homeostatic proliferation, in which di-
viding cells do not undergo activation or further maturation. The
mechanism of homeostatic proliferation differs between cell types.
Naïve T lymphocytes depend on self-antigen and IL-7 as signals
for homeostatic proliferation. IL-7 therapy is an attractive strategy
for promoting post-transplant thymopoiesis but may be compli-
cated by exacerbation of GVHD. Recent murine experiments sug-
gest that expansion of mature T lymphocytes by IL-7 may have a
paradoxical inhibitory effect on thymopoiesis. Some approaches
for translation of these experimental concepts into empirical stud-
ies in UCBCT will be described.
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INFECTIOUS DISEASE COMPLICATIONS AFTER UNRELATED DONOR
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN: IM-
PACT OF STEM CELL SOURCE
Barker, J., Wagner, J.E. Blood and Marrow Transplant Program,
University of Minnesota, Minneapolis, MN.
Umbilical cord blood (UCB) is being increasingly used as an
alternative source of hematopoietic stem cells (HSC) for unrelated
donor (URD) transplantation. However, how infection risk after
UCB transplantation (UCBT) compares with that seen after URD
bone marrow (BM) transplantation (BMT) is not known. There-
fore, we conducted a retrospective comparison of serious infectious
complications in the ﬁrst 2 years after HSC transplant in children
transplanted for hematologic malignancy at the University of Min-
nesota. Our hypothesis was that due to HLA disparity, delayed
neutrophil recovery, and the naivety of the neonatal immune sys-
tem, UCBT recipients may be at a higher risk of both early and late
infectious complications compared to recipients of unmanipulated
BM. In this retrospective analysis, there were 136 children (18
years of age) with a hematological malignancy who received cyclo-
phosphamide 120 mg/kg and total body irradiation (TBI 1320-
1375 cGy) followed by the transplantation of unmanipulated bone
marrow (BM, n  52), T cell depleted marrow (TCD, n  24), or
umbilical cord blood (n 60). Overall, the cumulative incidence of
one or more serious infections for the entire period was compara-
ble between groups (BM 81%, TCD 83%, UCB 90%; p  0.12).
Analysis of infection density (episodes of serious infection/1000
patient days) within the time periods days 0-42, 43-100, and 101-
Second Annual International UCB Symposium
737BB&MT
180 revealed no differences except a signiﬁcantly greater risk of
viral infections in TCD recipients from day 0-42 (TCD vs BM RR
3.5, p  0.02). After day 180, TCD recipients had the greatest
infection risk, whereas UCB recipients had the lowest risk TCD vs
BM RR 3.1, p 0.03; UCB vs BM RR 0.5, p 0.23). Multivariate
Cox regression analysis revealed that age 8 years, TCD, and
severe acute GVHD were each associated with increased infection
risk. These data suggest that the immune reconstitution after UCB
transplantation is superior to that seen with TCD, and is as good
as with unmanipulated BM.
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TRANSPLANTATION OF EX VIVO EXPANDED CORD BLOOD
Shpall, E.J.1, McNiece, I.K.2, de Lima, M.1, McMannis, J.D.1, Robin-
son, S.1, Peled, T.3, Champlin, R.E.1, 1. The M.D. Anderson Bone
Marrow Transplant Department, Houston, TX; 2. Johns Hopkins On-
cology Center, Baltimore, MD; Gamida Cell Ltd.
Umbilical cord blood (CB) from unrelated donors is increasingly
used to restore hematopoiesis after myeloablative or more recently,
nonmyeloablative therapy. CB transplants are associated with
higher rates of delayed and failed engraftment than are bone
marrow transplants, particularly for adult patients. At the Univer-
sity of Colorado, we studied the ex vivo expansion of CB in an
attempt to improve time to engraftment and reduce the graft
failure rate in the recipients. In the study, 43 patients with hema-
tologic malignancies (n  40) or breast cancer (n  3) received
high-dose therapy followed by unrelated allogeneic CB transplan-
tation [1]. A fraction of each patient’s CB allograft was CD34-
selected and cultured ex vivo for 10 or 14 days prior to transplan-
tation in deﬁned media with stem cell factor (SCF), granulocyte
colony-stimulating factor (G-CSF), and megakaryocyte growth
and differentiation factor (MGDF). The remainder of the CB graft
was infused without further manipulation. Two sequential cohorts
of patients were accrued to the study. The ﬁrst cohort had 40% and
the second cohort had 60% of their CB graft expanded. This study
demonstrated that the CD34 selection and ex vivo expansion of CB
prior to transplantation is feasible. The engraftment failure rate
was relatively low, and the time to neutrophil in large adults was in
the range reported for pediatric recipients of much larger CB cell
doses.
In the successor cord expansion trial being conducted at the
M.D. Anderson Cancer Center, several changes in the approach
have been made. Patients with hematologic malignancies are now
being randomized to receive either two unmanipulated CB units or
one unmanipulated unit and one unit from which all the cells are
expanded ex vivo. For the patients randomized to expansion, on
day 14 one of their cord units is AC133-selected using the
CliniMACS device. The AC133-negative fraction containing the
T cells is frozen and the AC133 fraction is cultured ex vivo for 14
days in media containing SCF, G-CSF and thrombopoietin
(TPO). Following administration of the preparative regimen, on
Day 0, the second unmanipulated CB unit is infused, followed by
the thawed AC133-negative fraction and ﬁnally, the fraction which
has been in culture for two weeks. This trial was recently initiated
and accrual is in progress.
Another expansion trial technology involves the use of a copper
chelating agent, which has been shown by Peled et al to enhance
the expansion of a more primitive CD34 CB population when
combined with early acting growth factors. A clinical trial employ-
ing this technology is in progress at M.D. Anderson. Patients with
hematologic malignancies undergoing CB transplantation, with a
unit that is cryopreserved in two fractions are eligible for the study.
Twenty one days prior to infusion, the AC133 cells are isolated
from the smaller cord fraction using the CliniMACS device and
cultured for three weeks in media containing interleukin-6 TPO,
FLT-3, SCF, and the copper chelator tetraethylenepentamine
(TEPA). The patients then receive high-dose therapy with the
infusion of the larger, unmanipulated CB fraction on day 0, and
infusion of the smaller expanded fraction of day1. Thus far eight
patients have been enrolled on the study and the results will be
forthcoming.
Future directions include the use of mesenchymal stem cells as a
supportive stroma for the expansion of CB mononuclear cell pro-
genitors, developed by McNiece et al. This approach would obvi-
ate the need for CD34 or AC133-selection, as those procedures are
associated with substantial losses of CD34 CB cells
1. Shpall EJ, Quinones R, Giller R, et al. Transplantation of ex
vivo expanded cord blood. Biol Blood Marrow Transplant.
2002;8:368-376.
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CGMP MANUFACTURE OF THE MULTIPOTENT ADULT PROGENITOR
CELL (MAPC) AND STRATEGY FOR CLINICAL TESTING
Wagner, J.E., Verfaillie, C.M. Blood and Marrow Transplant Program
and Stem Cell Institute, University of Minnesota, Minneapolis, MN.
MAPC are a rare cell population found in adult bone marrow
(BM) that proliferate for extended periods without obvious senes-
cence. MAPC differentiate into mesodermal, neuroectodermal and
endodermal tissues. Further, MAPC contribute to most somatic
tissues when injected into an early blastocyst, and can engraft in
post-natal animals where they can differentiate into tissue-speciﬁc
cell types. Therefore, we hypothesize that MAPC may be useful in
the treatment of a variety of degenerative and inherited diseases
and traumatic injury. Prior to clinical testing, however, MAPC
must be produced in accordance with cGMP. This will require: 1)
production of clinical grade reagents (i.e., sterile, endotoxin and
mycoplasma free), 2) optimization of process components to min-
imize surface areas required for cell expansion, 3) deﬁnition of a
closed cell expansion system integrated with blood cell processing
procedures and equipment, 4) process validation and establishment
of quality assurance documentation, and validation of the assays
themselves used for quality control (QC) and product release.
After clinical manufacture, MAPC lot release criteria will include
a demonstration of: 1) purity as measured by cell surface antigen
expression (MAPC are CD45neg, MHCneg, CD13) and quan-
titative RT-PCR for the transcription factor oct4; 2) proliferative
capacity as measured ability to be promulgated in culture for 70
doublings without telomere shortening and without cytogenetic
abnormalities, and 3) pluripotency, as demonstrated by ability to
differentiate into tissue-speciﬁc cells of each lineage. In parallel to
efforts to develop a large scale clinical manufacture procedure,
there has been considerable effort to the selection of a clinical
model for the testing of MAPC. As it is hypothesized that MAPC
will distribute and proliferate in tissues of various organs, partic-
ularly in response to tissue injury, the ﬁrst clinical trial will be in
recipients of high dose chemoradiotherapy in whom high regimen
related toxicity (i.e., as evidenced by injury to the gastrointestinal
tract, liver and lung) severely limits survival.
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ISOLATION OF NON-HEMATOPOIETIC STEM CELLS FROM UMBILICAL
CORD BLOOD
Wernet, P., Fischer, J., Caplan, A., Zanjani, E., Müller, H.W., Knip-
per, A., Kögler, G.
An intrinsically pluripotent, CD45 negative population from
placental cord blood, termed unrestricted somatic stem cells
(USSC) as a rare population grows adherently and can be expanded
to large quantities of cells without losing pluripotency. Thus, in
vitro USSC homogeneous differentiation into osteoblasts, chon-
droblasts, adipocytes, hematopoietic and neural cells including
astrocytes and neurons expressing neuroﬁlament, sodium channel
protein and various neurotransmitter phenotypes are demon-
strated. Stereotactic implantation of USSC into intact adult rat
brain revealed that human Tau-positive cells persisted for several
months, showing migratory activity and a typical neuron-like mor-
phology. In vivo differentiation of USSC along mesodermal and
endodermal pathways was demonstrated in animal models. Bony
reconstitution was observed after transplantation of USSC-loaded
calcium phosphate cylinders in nude rat femurs. Chondrogenesis
occurred after transplanting cell-loaded Gelfoam sponges into
nude mice. Transplantation of USSC in a non-injury model, the
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